Search results for "STAGE"

showing 10 items of 1393 documents

Design and manufacturing feasibility of ITER TBM Frame and Dummy TBMs

2016

Abstract The operation and test of mock-ups of tritium breeding blankets relevant for a future commercial reactor is one of the goals of the ITER machine. To accomplish this goal, mock-ups of breeding blankets, called Test Blanket Modules (TBMs), are installed in three ITER equatorial ports. Each TBM and the associated shield form a TBM-set that is mechanically attached to a steel frame called TBM Frame. A Frame and two TBM-Sets form a TBM Port Plug (TBM PP). The ITER Organization is responsible for the design and manufacture of the TBM Frames and of the Dummy TBMs that could replace the TBM-sets in case they were not available. This paper describes the recent results of the design supporti…

Light nucleusDesign stageComputer scienceMechanical EngineeringNuclear engineeringFrame (networking)Iron alloysIter tokamakBlanket01 natural sciences010305 fluids & plasmasNuclear Energy and EngineeringSteel frameShieldITER Test blanket module (TBM) TBM port plug (TBM PP) Frame Dummy TBM0103 physical sciencesGeneral Materials Science010306 general physicsSettore ING-IND/19 - Impianti NucleariCivil and Structural Engineering
researchProduct

Spatio-Chromatic Adaptation via Higher-Order Canonical Correlation Analysis of Natural Images

2014

Independent component and canonical correlation analysis are two general-purpose statistical methods with wide applicability. In neuroscience, independent component analysis of chromatic natural images explains the spatio-chromatic structure of primary cortical receptive fields in terms of properties of the visual environment. Canonical correlation analysis explains similarly chromatic adaptation to different illuminations. But, as we show in this paper, neither of the two methods generalizes well to explain both spatio-chromatic processing and adaptation at the same time. We propose a statistical method which combines the desirable properties of independent component and canonical correlat…

LightVisual SystemRECEPTIVE-FIELD PROPERTIESlcsh:MedicineSocial and Behavioral SciencesBioinformaticsSTRIATE CORTEXCOLOR APPEARANCEImage Processing Computer-AssistedPsychophysicsPsychologylcsh:ScienceVisual CortexMathematicsCoding MechanismsMultidisciplinarySPECTRAL DESCRIPTIONSStatisticsSensory SystemsPRIMARY VISUAL-CORTEXDATA SETSPrincipal component analysisSensory PerceptionSPATIAL STRUCTURECanonical correlationAlgorithmsColor PerceptionResearch ArticleeducationColorCHROMATIC MECHANISMS114 Physical sciencesArtificial IntelligenceComponent (UML)PsychophysicsHumansComputer SimulationChromatic scaleStatistical MethodsBiologyProbabilityComputational NeuroscienceModels StatisticalINDEPENDENT COMPONENT ANALYSISbusiness.industrylcsh:RNeurosciencesComputational BiologyPattern recognitionIndependent component analysisData set2-STAGE LINEAR RECOVERYChromatic adaptationlcsh:QArtificial intelligencebusinessPhotic StimulationMathematicsNeurosciencePLoS ONE
researchProduct

Hepatobiliary phase in cirrhotic patients with different Model for End-stage Liver Disease score: comparison of the performance of gadoxetic acid to …

2018

The purpose of this study was to compare the performance of gadobenate dimeglumine–enhanced MRI and gadoxetic acid–enhanced MRI in the hepatobiliary phase (HBP) in cirrhotic patients with different degrees of liver dysfunction. In this retrospective cross-sectional study, we analyzed the unenhanced phase and the HBP of 131 gadobenate dimeglumine–enhanced MRI examinations (gadobenate dimeglumine group) and 127 gadoxetic acid–enhanced MRI examinations (gadoxetic acid group) performed in 249 cirrhotic patients (181 men and 68 women; mean age, 64.8 years) from August 2011 to April 2017. For each MRI, the contrast enhancement index of the liver parenchyma was calculated and correlated to the Mod…

Liver CirrhosisAdultMaleGadolinium DTPAGadoxetic acidmedicine.medical_specialtyLiver CirrhosiContrast MediaSensitivity and SpecificitySeverity of Illness Index030218 nuclear medicine & medical imagingGadobenic acid03 medical and health sciencesLiver diseaseYoung Adult0302 clinical medicineModel for End-Stage Liver DiseaseMeglumineGadobenic acidRetrospective StudiemedicineGadolinium ethoxybenzyl DTPAOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingRetrospective StudiesNeuroradiologyAgedAged 80 and overCross-Sectional Studiemedicine.diagnostic_testMegluminebusiness.industryMagnetic resonance imagingGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseMagnetic Resonance ImagingCross-Sectional Studies030220 oncology & carcinogenesisFemaleRadiologyNuclear medicinebusinessmedicine.drugHuman
researchProduct

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

2014

BACKGROUND & AIMS: Fibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N-terminal propeptide of type III collagen (Pro-C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients. METHOD: Pro-C3 and C3M were measured by ELISA in plasma from CHC patients (n = 194) from a prior phase II antifibrotic trial (NCT00244751). Plasma samples and paired liver biopsies were obtained at baseline and after 1-year. Patients were stratified according to Ishak stages 2-4. Internal cross-validation w…

Liver CirrhosisCollagen Type III/bloodPathologymedicine.medical_specialtyLiver fibrosisEnzyme-Linked Immunosorbent AssayGastroenterologySerologyExtracellular matrixCohort StudiesCollagen Type IIIFibrosisPredictive Value of TestsInternal medicinemedicineHumansStage (cooking)Hepatologybusiness.industryFibroTestBiomarkerHepatitis C ChronicPrognosismedicine.diseaseCollagen Type IIIPredictive value of testsMultivariate AnalysisExtracellular matrix remodellingDisease ProgressionBiomarker (medicine)Hepatitis C Chronic/bloodbusinessLiver Cirrhosis/diagnosisBiomarkers/bloodBiomarkersLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy

2018

Introduction. To evaluate the characteristics of alcohol-related chronic liver disease (CLD) in Italy and their potential changes over time. Patients and Methods. Subjects with CLD were enrolled in two national surveys performed in 2001 and in 2014 in Italy. The two surveys prospectively recruited patients aged ≥ 18 years referring to more than 80 Italian liver units scattered all over the country using similar clinical approach, analytical methods, and threshold of risky alcohol intake definition (≥ 3 units/day in men and ≥ 2 units/day in women). Results. Out of 12,256 enrolled subjects, 2,717 (22.2%) reported a risky alcohol intake. Of them, anti-HCV positive was observed in 48.3% of subj…

Liver CirrhosisMaleCirrhosisChronic liver diseaseHealth Risk BehaviorsHealth Risk BehaviorLiver disease0302 clinical medicineStage (cooking)ChronicLiver DiseasesGastroenterologyGeneral MedicineHepatitis CHealth SurveyMiddle AgedAlcoholicHepatitis CAlcoholismItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleSex ratioAdult; Aged; Alcohol Drinking; Alcoholism; Chronic Disease; Female; Health Risk Behaviors; Health Surveys; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Diseases Alcoholic; Male; Middle AgedResearch ArticleHumanAdultmedicine.medical_specialtyArticle SubjectAlcohol DrinkingLiver Cirrhosi03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Liver Diseases AlcoholicAgedHepatologybusiness.industryHepatologyHepatitis C AntibodiesHepatitis C Chronicmedicine.diseaseHealth SurveysAgeingChronic Diseaselcsh:Diseases of the digestive system. GastroenterologybusinessHepatitis C Antibodie
researchProduct

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombo…

2015

Background: A 24-48-week course of interferon-based therapy poorly tolerated in hepatitis C virus (HCV) cirrhosis patients with thrombocytopenia. Aim of the study was to identify patients at low-risk of liver-related complications over a 12-week course of interferon-based therapy. Methods: We assessed the rate of complications and death during the first 12 weeks of interferon-based therapy in HCV cirrhotics with thrombocytopenia (platelets ≤75×109/L) enrolled in the ENABLE-1 and -2 phase 3 randomised controlled trials. Results: Overall, among 1441 patients, 89 complications (6.9%) and 10 deaths (0.7%) were observed within the first 12 weeks of therapy. At univariate analysis baseline albumi…

Liver CirrhosisMaleCirrhosisHepacivirusmedicine.disease_causeGastroenterologyBenzoatesSeverity of Illness IndexLiver-related complicationchemistry.chemical_compoundModel for End-Stage Liver DiseaseRisk FactorsAlbumin levelHydrazineMultivariate AnalysiAged 80 and overUnivariate analysisGastroenterologyHepatitis CMiddle AgedHydrazinesTreatment OutcomeFemaleHumanAdultmedicine.medical_specialtyLiver CirrhosiHepatitis C virusEltrombopagAlpha interferonAntiviral AgentsBenzoateInternal medicineAlbuminsRibavirinmedicineHumansLiver-related mortalityAgedAntiviral AgentHepaciviruHepatologybusiness.industryAlbuminRisk FactorRibavirinMELD scoreInterferon-alphaHepatitis C Chronicmedicine.diseaseThrombocytopeniaSurgerychemistryPyrazoleMultivariate AnalysisPyrazolesbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients

2014

Summary Background Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. Aim To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. Methods Analysis of the database from a prospective inception cohort of 494 patients. Decompensation was defined by ascites, bleeding, jaundice or encephalopathy. Explored potential prognostic stages: 1, compensated cirrhosis without oesophago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without other complications; 4, first nonbleeding decompensation; 5, any second decompensating event.…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaDatabases Factualmedicine.medical_treatmentLiver transplantationGastroenterologyCohort StudiesModel for End-Stage Liver DiseaseAscitesEsophageal and Gastric VariceMedicinePharmacology (medical)Prospective StudiesProspective cohort studyLiver NeoplasmsGastroenterologyAscitesJaundiceMiddle AgedPrognosisLiver NeoplasmAsciteDisease ProgressionFemalemedicine.symptomHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularPrognosiLiver CirrhosiJaundiceEsophageal and Gastric VaricesRisk AssessmentFollow-Up StudieInternal medicineHumansDecompensationAgedHepatologybusiness.industrymedicine.diseaseLiver TransplantationProspective StudieCohort StudiebusinessVaricesFollow-Up Studies
researchProduct

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.

2011

Clinical outcomes of recurrent hepatitis C virus after liver transplantation are difficult to predict. We evaluated collagen proportionate area (CPA), a quantitative histological index, at 1 year with respect to the first episode of clinical decompensation. Patients with biopsies at 1 year after liver transplantation were evaluated by Ishak stage/grade, and biopsy samples stained with Sirius red for digital image analysis were evaluated for CPA. Cox regression was used to evaluate variables associated with first appearance of clinical decompensation. Receiver operating characteristic (ROC) curves were also used. A total of 135 patients with median follow-up of 76 months were evaluated. At 1…

Liver CirrhosisMaleCirrhosisTime FactorsPortal venous pressuremedicine.medical_treatmentBiopsyKaplan-Meier EstimateLiver transplantationmedicine.disease_causeGastroenterologyRecurrenceRisk FactorsLondonChildFirst episodemedicine.diagnostic_testMiddle AgedHepatitis CLiverFemaleCollagenAdultmedicine.medical_specialtyAdolescentHepatitis C virusHepatic VeinsRisk AssessmentSensitivity and SpecificityEnd Stage Liver DiseaseYoung AdultPredictive Value of TestsInternal medicineBiopsyImage Interpretation Computer-AssistedmedicineHumansDecompensationAgedProportional Hazards ModelsRetrospective StudiesTransplantationHepatologybusiness.industrymedicine.diseaseSurgeryLiver TransplantationTransplantationROC CurveSurgerybusinessVenous PressureLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.

2005

Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of th…

Liver CirrhosisMaleCirrhosisTime FactorsPrognostic systemGastroenterologyOily chemoembolizationHepatic ArteryCause of DeathAscitesValidationMedicineStage (cooking)CIRRHOSISUnivariate analysisAntibiotics AntineoplasticLiver NeoplasmsGastroenterologyLiver-TransplantationMiddle AgedHEPATOCELLULAR CARCINOMA; CIRRHOSIS; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; SURVIVAL; SIDE EFFECTSPrognosisTreatment OutcomeItalyRandomized controlled trialHepatocellular carcinomaSURVIVALFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularMultivariate-analysiTransarterial chemoembolizationInternal medicineSIDE EFFECTSCarcinomaHumansHEPATOCELLULAR CARCINOMAChemoembolization TherapeuticTranscatheter arterial chemoembolizationSurvival analysisAgedEpirubicinNeoplasm StagingCirrhosiHepatologybusiness.industrymedicine.diseaseSurvival AnalysisSurgeryLipiodol chemoembolizationTRANSCATHETER ARTERIAL CHEMOEMBOLIZATIONCase-Control StudiesMultivariate AnalysisbusinessFollow-Up StudiesClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct